CUE vs DASH · rev $9.3M vs P/E 76, rev $13.72B
Cue Biopharma (CUE) versus DoorDash, Inc. Class A Common Stock (DASH) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
DoorDash, Inc. Class A Common Stock (DASH) is a internet retail company listed on US.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
Latest reported DASH revenue for 2025-12-31 was $13.72B. Net income was $935.0M. Revenue was up 27.9% from 2024-12-31 to 2025-12-31. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
CUE currently screens at market cap $59.5M. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
Not investment advice. Open the CUE and DASH stock pages for the full models.
Not investment advice.